Structure Search

    Search

    Online Support

  •  Customer service

    Location: Industrial Info

WHO released list of essential drugs 2017, the first mention of antibiotic classification standards

2017-06-08 来源:亚科官网
 8 June 2017
 
  Recently, the World Health Organization (WHO) has made the most significant revisions to its list of antibiotics in its list of essential drugs in the past 40 years. The list of essential medicines in 2017 has added new elements, including new recommendations for antibiotics that can be used for common infections and should be kept to the most serious cases and other supplementary recommendations.
 
New advice: three types of antibiotics
 
  In the new version of the WHO Essential Drug Standards List, WHO experts divided antibiotics into three categories: available categories, caution classes and standby categories, and made recommendations on when each category should be used:
 
  "Available class": c antibiotics an be widely used at any time for the treatment of a wide range of common infection. For example, amoxicillin; "cautious class": that is used with caution, it is recommended for a small number of infections for primary or secondary treatment. For example, the use of ciprofloxacin for the treatment of cystitis (a urinary tract infection) and upper respiratory tract infections (such as pharyngitis and bacterial sinusitis) should be drastically reduced in order to avoid further development of drug resistance; “standby class”: that is reserved for use, should be considered as the last resort of antibiotics such as colistin and some cephalosporins, etc., and should only be used in the most severe cases where all other alternatives are malfunctioning.
 
  The purpose of this revision is to ensure that the patient has antibiotics available when needed and to ensure that the infection is correct for the antibiotic. This should enhance the effectiveness of the treatment, reduce the development of resistant bacteria, and protect the efficacy of antibiotics as a "last resort" when all other drugs fail.
 
Other supplements
 
  The updated list of essential drugs also includes several new drugs, which include:
 
Dasatinib and nilotinib: two oral cancer drugs for the treatment of chronic myeloid leukemia that is resistant to standard therapy;
Sofloxacin + veptapine: the first combination therapy for the treatment of all six types of hepatitis C;
Dobutyridine tablets: For the treatment of HIV infection, the latest evidence shows the safety of the drug, efficacy and resistance to high resistance;
Tenofovir or in combination with emtricitabine or lamivudine: pre-exposure prophylaxis to prevent HIV infection;
Delamanid and Clofazimine: Delamanid—In the treatment of children and adolescents suffering from MDR-TB, Clofazimine—children and adults who are used to treat MDR-resistant tuberculosis;
Isoniazid, rifampicin, ethambutol and pyrazinamide: for the treatment of tuberculosis in children;
Fentanyl skin patch and methadone: used to relieve pain in cancer patients, increase access to dying care drugs.
 
  Because antibiotic drugs are widely used, the problem of bacterial resistance has become increasingly serious in recent years. The new WHO list helps health system planners and prescribers to ensure that those in need are able to obtain and be able to obtain the right antibiotics to prevent deterioration of drug problems.
 
 
Edited by Suzhou Yacoo Science Co., Ltd.